Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 230 participants.

Also called NCT01442987

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 230 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01442987
Other papers using this trial's data
  • Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study Clinical therapeutics, 2016-10 DOI, PubMed 27742464

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01442987. Randomized; double masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
Condition
Hypertension
Condition
Hyperlipidemia
Intervention (Drug)
Irbesartan/Atorvastatin A
Intervention (Drug)
Irbesartan
Intervention (Drug)
Atorvastatin A
Intervention (Drug)
Placebo
Intervention (Drug)
Irbesartan/Atorvastatin B
Intervention (Drug)
Atorvastatin B
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct01442987
Content hash
3674442751f1f1d6a6c31bff209ff6fd30585b3b6d625c015bea1c6033bd1fa0